Artivion, Inc. (NYSE:AORT) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its holdings in Artivion, Inc. (NYSE:AORT) by 4.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 107,199 shares of the company’s stock after selling 4,980 shares during the quarter. Victory Capital Management Inc. owned 0.26% of Artivion worth $2,854,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Perceptive Advisors LLC boosted its holdings in Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after purchasing an additional 124,725 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after purchasing an additional 33,982 shares during the last quarter. First Eagle Investment Management LLC boosted its holdings in Artivion by 4.9% in the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after purchasing an additional 27,906 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Artivion by 0.7% in the second quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock valued at $7,746,000 after purchasing an additional 2,018 shares during the last quarter. Finally, Public Sector Pension Investment Board boosted its holdings in Artivion by 7.8% in the second quarter. Public Sector Pension Investment Board now owns 87,273 shares of the company’s stock valued at $2,239,000 after purchasing an additional 6,344 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. JMP Securities assumed coverage on shares of Artivion in a research note on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price on the stock. Oppenheimer increased their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of Artivion in a research note on Friday, September 27th. Finally, Stifel Nicolaus increased their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $31.00.

Artivion Stock Up 0.9 %

AORT opened at $28.27 on Friday. Artivion, Inc. has a twelve month low of $16.48 and a twelve month high of $30.00. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average price of $26.62 and a 200 day moving average price of $25.60. The company has a market cap of $1.19 billion, a PE ratio of -1,413.50 and a beta of 1.75.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 12,430 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This represents a 8.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 3,167 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the sale, the senior vice president now owns 161,932 shares of the company’s stock, valued at approximately $4,299,294.60. The trade was a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.10% of the company’s stock.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.